Reliable Conjugation Technology for Precision Medicine
  • Home
  • Pipeline
  • The Technology
    • Peptide Asx Ligase (PALs)
    • History
    • Strong Science
  • Management
    • Directors & Cofounders
    • Scientific Advisory Board
    • Executive Scientific Team
  • News
  • Contact us
  • More
    • Home
    • Pipeline
    • The Technology
      • Peptide Asx Ligase (PALs)
      • History
      • Strong Science
    • Management
      • Directors & Cofounders
      • Scientific Advisory Board
      • Executive Scientific Team
    • News
    • Contact us
Reliable Conjugation Technology for Precision Medicine
  • Home
  • Pipeline
  • The Technology
    • Peptide Asx Ligase (PALs)
    • History
    • Strong Science
  • Management
    • Directors & Cofounders
    • Scientific Advisory Board
    • Executive Scientific Team
  • News
  • Contact us

Innovative Technology

  • The core technology of the platform lies in the use of Peptide Asparaginyl Ligases (PALs) to conjugate active drugs or any other payloads to proteins.
  • Singzyme's platform for antibodies and nanobodies engineering and conjugation provides a one- stop solution to the problems faced by Antibody Drug Conjugates developers, stemming from their manufacturing process. Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.

Peptide Asparaginyl Ligases (PAL)

Use of peptide ligases for site-specific conjugation

Our platform leverages peptide ligases to achieve precise, site-specific conjugation with unmatched control.

A family of enzymes for combinatorial conjugation

We offer a versatile family of ligases enabling a broad range of conjugation strategies across different payloads and formats.

Up to 20,000 x faster reaction than other enzymes

  • Our ligases catalyze conjugation reactions up to 20,000 times faster than traditional enzymatic methods, accelerating manufacturing timelines.

Minimal footprint on the final product

  • The ligation process leaves only a minimal, non-immunogenic footprint, preserving the native structure of the therapeutic.

Low impact on antibody activity/tumour penetration

Conjugation preserves antibody binding and optimizes tumor penetration for superior therapeutic efficacy.

About Us

Applications

  • Cancer immunotherapy 
    • Controlled Drug to Antibody Ratio
    • Homogenous Product
    • One Step process 
    • Faster and cheaper production of effective antibody-drug-conjugates
    • Minimal footprint on the final product 
    • Attach Multiple payloads with high efficiency


  • Imaging for disease diagnosis
    • Ultra-fast production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs)
    • Minimal radioactive waste due to the highest conjugation efficiency.
    • Lower toxicity (Low Kidney retention)


Copyright © 2025 Singzyme

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept